Pliant Therapeutics Q3 net loss narrows to $26.3 mln

Pliant Therapeutics

06/11/2025 21:52

Overview

Pliant Q3 net loss narrows to $26.3 mln, driven by BEACON-IPF discontinuation

Company completed voluntary prepayment of Oxford Finance loan

Outlook

BEACON-IPF close out activities to be completed in Q4 2025

Result Drivers

R&D EXPENSES - Decrease primarily due to discontinuation of BEACON-IPF trial

ADMINISTRATIVE COSTS - Decline due to strategic workforce restructuring

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$26.30 mln
Q3 Operating Expenses
-$28.27 mln
Q3 Operating Income
-$28.27 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 45.3% above its November 5 closing price of $1.64

Press Release: ID:nGNX8287tf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)